Soluble Tumour Necrosis Factor-α Receptor I and Interleukin-6 as Markers of Activity in Thyrotoxic Graves' Disease

Hormone and Metabolic Research

Volumn 35, Issue 7, 2003, Pages 427-433

  Pichler, R ^a   Maschek, W ^a   Hatzl Griesenhofer, M ^a   Huber, H ^a   Crespillo Gomez C ^b   Berg, J ^a  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Cytokines; Graves' disease; Hyperthyreosis; TNF receptor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; THYROTROPIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; AUTOIMMUNITY; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GRAVES DISEASE; HUMAN; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS; THYROTOXICOSIS;

ADULT; C-REACTIVE PROTEIN; FEMALE; GRAVES DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; THYROTROPIN; TRIIODOTHYRONINE;

EID: 0242637020     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41624     Document Type: Article

References (34)

1. Roura-Mir C, Catálfamo M, Sospedra M, Alcalde L, Pujol-Borrell R, Jaraquemada D. Single-cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto's and Graves' disease. Eur J Immunol 1997; 27: 3290-3302
2. Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JAH, Welsh KI. Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab 2000; 85: 1984-1988
3. Rasmussen AK, Hartoft-Nielsen M, Feldt-Rasmussen U. Models to study the pathogenesis of thyroid autoimmunity. Biochimie 1999; 81: 511-515
4. Ajjan RA, Watson PF, Weetman AP. Cytokines and thyroid function. Adv Neuroimmunol 1996; 6: 359-386
5. Aust G, Heuer M, Laue S, Lehmann I, Hofmann A, Heldin NE, Scherbaum WA. Expression of tumour necrosis factor-alpha (TNF-alpha) mRNA and protein in pathological thyroid tissue and carcinoma cell lines. Clin Exp Immunol 1996; 105: 148-154
6. Nophar Y, Kemper O, Brakebush C, Englemann H, Zwang R, Aderka D, Holtmann H, Wallach D. Soluble forms of human necrosis factor (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form encodes both the cell surface and a soluble form of the receptor. Eur Molec Biol Organ J 1990; 9: 3269-3273
7. Hohmann HP, Remy R, Brockhaus M, van Loon APGM. Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem 1989; 264: 14927-14934
8. Pang XP, Yoshimura M, Hershman JM. Suppression of rat thyrotroph and thyroid cell function by tumor necrosis factor-alpha. Thyroid 1993; 3: 325-330
9. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 1999; 84: 435-439
10. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, Roti E. Serum concentrations of proinflammatory cytokines in Graves's disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Europ J Endocrinol 2000; 143: 197-202
11. Komiya I, Yamada T, Sato A, Kouki T, Nishimori T, Takasu N. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin-13. J Clin Endocrinol Metab 2001; 86: 3540-3544
12. Celik I, Akalin S, Erbas T. Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment. Eur J Endocrinol 1995; 132: 668-672
13. Akalin A, Colak Ö, Alatas Ö, Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol 2002; 57: 125-129
14. Lantz M, Malik S, Slevin ML, Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990; 2: 402-406
15. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995; 54: 1-8
16. Modzelewski B. Release of tumor necrosis factor alfa and its soluble receptor p55 in clinical septic syndrome. Arch Immunol Ther Exp 1997; 45: 213-219
17. Bartalena L, Brogioni S, Grasso L, Martino E. Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration. J Endocrinol Invest 1993; 16: 213-218
18. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997; 40: 1096-1105
19. Herrmann W, Ecker D, Quast S, Klieden M, Rose S, Marzi I. Comparison of procalcitonin, sCD14 and interleukin-6 values in septic patients. Clin Chem Lab Med 2000; 38: 41-46
20. Pichler R, Berg J, Crespillo C, Hatzl-Griesenhofer M, Huber H, Maschek W. Hipertiroidismo de Graves y modulación por citoquinas proinflamatorias: el papel de TNF-R e IL-6 en la fase aguda. Endocrinología 2001; 48 (supl. 2): 53 (abstract)
21. Fraunberger P, Pfeiffer M, Cremer P, Holler E, Nagel D, Dehart I, Thein M, Walli AK, Seidel D. Validation of an automated enzyme immunoassay for Interleukin-6 for routine clinical use. Clin Chem Lab Med 1998; 36: 797-801
22. Heilig B, Wermann M, Gallati H, Brockhaus M, Berke B, Egen O, Pezzutto A, Hunstein W. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin Investig 1992; 70: 22-27
23. Mariotti S, Caturegli P, Barbesino G, Marino M, Del Prete GF, Chiovato L, Tonacchera M, de Carli M, Pinchera A. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases. Clin Endocrinol 1992; 37: 415-422
24. Smallridge RC, Tsokos GC, Burman KD, Porter L, Cranston T, Sfikakis PP, Solomon BL. Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis. Clin Diagn Lab Immunol 1997; 4: 583-586
25. Díez JJ, Hernanz A, Medina S, Bayón C, Iglesias P. Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol 2002; 57: 515-521
26. Komorowski J, Jankiewicz J, Robak T, Blasinska-Morawiec M, Stepien H. Cytokines serum levels as the markers of thyroid activation in Graves' disease. Immunol Lett 1998; 60: 143-148
27. Wakelkamp IMMJ, Gerding MN, van der Meer JWC, Prummel MF, Wiersinga WM. Both Th1 and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy. Clin Exp Immunol 2000; 121: 453-457
28. Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 1994; 78: 98-102
29. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr WR et al. Prospective multicenter study on the prediction of relapse after antithyroid drug treatment in patients with Graves'disease. Acta Endocrinol 1989; 120: 689-701
30. Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R. Prediction of Remission or Relapse for Graves' Hyperthyroidism by the Combined Determination of Stimulating, Blocking and Binding TSH-Receptor Antibodies after the Withdrawal of Antithyroid Drug Treatment. Horm Metab Res 2002; 34: 383-388
31. Nygaard B, Jarlov AE, Kristensen LO, Faber J. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 1311-treatment of Graves' disease and nodular goiter. Horm Metab Res 2000; 32: 283-287
32. Heufelder AE. Pathogenesis of Graves' ophthalmopathy: recent controversies and progress. Eur J Endocrinol 1995; 132: 532-541
33. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000; 85: 1194-1199
34. Mysliwiec J, Kretowski A, Topolska J, Siewko K, Jakubczyk D, Szelachowska M, Mikita A, Kinalska I. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids. Horm Metab Res 2001; 33: 739-743